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Objective: Atrial fibrillation is a very common
heart arrhythmia, associated with a five-fold in-
crease in the risk of embolic strokes. Treatment
strategies encompass palliative drugs or surgical
procedures all of which can restore sinus rhythm.
Unfortunately, atria often fail to recover their me-
chanical function and patients therefore require
lifelong anticoagulation therapy. A motorless vol-
ume displacing device (Atripump®) based on arti-
ficial muscle technology, positioned on the exter-
nal surface of atrium could avoid the need of oral
anticoagulation and its haemorrhagic complica-
tions. An animal study was conducted in order to
assess the haemodynamic effects that such a pump
could provide. 
Methods: Atripump is a dome-shape silicone-
coated nitinol actuator sewn on the external sur-
face of the atrium. It is driven by a pacemaker-like
control unit. Five non-anticoagulated sheep were
selected for this experiment. The right atrium was
surgically exposed, the device sutured and con-
nected. Haemodynamic parameters and intracar-
diac ultrasound (ICUS) data were recorded in
each animal and under three conditions; baseline;
atrial fibrillation (AF); atripump assisted AF
(aaAF). 
Results: In two animals, after 20 min of AF,
small thrombi appeared in the right atrial appen-
dix and were washed out once the pump was
turned on. Assistance also enhanced atrial ejection
fraction. 31% baseline; 5% during AF; 20%
under aaAF. Right atrial systolic surfaces (cm2)
were; 5.2 ± 0.3 baseline; 6.2 ± 0.1 AF; 5.4 ± 0.3
aaAF.
Conclusion: This compact and reliable pump
seems to restore the atrial “kick” and prevents
embolic events. It could avoid long-term antico-
agulation therapy and open new hopes in the care
of end-stage heart failure.
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Summary
Atrial fibrillation (AF) is the most common
abnormal heart rhythm encountered in medical
practice. It is a rapid atrial arrhythmia also charac-
terised by irregular or absent mechanical activity
[1]. In the western world, 5% of the population is
affected and long-term studies reveal that the
mortality of these patients is twice that of persons
with normal sinus rhythm [2].
AF is associated with a five-fold increase in
the risk of cardioembolic strokes due to blood sta-
sis and therefore clotting phenomena [3, 4].
These strokes are the most severe ones, with long
transient ischaemic attacks, presumably due to
embolisation of larger particles than in carotid
disease. Cognitive defects may be detected to-
gether with asymptomatic embolic events on
brain-CT, reducing the quality of life (QOL) [5].
Statistical significant fall in patient’s activity and
heart rate variability also occur. [6]. Finally, de-
creased ventricular filling time and loss of atrial
contraction make AF an independent risk factor
for chronic heart failure (HF) [7–9]. 
Based on these observations, we elaborated an
experimental atrial assistance device that restores
the missing mechanical support during AF. Fur-
ther clinical aims could be: 
– prevention of embolism, or at least be an overall
physiological assessment of the problem of
atrial stunning 
– a better ventricular preload, that could become
significant when preserving the little cardiovas-
cular performance left, in patients with reduced
ventricular function.
Until now, and because AF has detrimental
sequelae, many therapeutic strategies have been
developed. Actual treatments embrace two main
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alternatives that both require a challenging de-
cision in clinical management. First, the use of
palliative drugs such as negative chronotropes
combined with lifelong oral anticoagulation (ac-
cording to the CHADS2 score). Secondly, the
only surgical or endovascular intervention that
can potentially cure AF, known as the AFib ra-
diofrequency ablation procedure. 
The first Cox-Maze was performed in 1988
and is based on the fact that AF results from mul-
tiple microreentry circuits in the atria. The oper-
ator creates precise microlesions, using cryo- or
thermo ablation, creating electrical blind alleys in
which there are no longer sustainable multiple
wavelets [10–12]. This extensive procedure has
some negative effects on atrial mechanical work.
Postoperative patients assessed by echocardiogra-
phy showed, five years later, a significant loss in
atrial contractility and an increase in atrial size
[13]. Today, the AFib ablation uses radiofrequency
(RF) after precise mapping and is reported to be
effective in restoring sinus rhythm and preserving
some atrial function. Ablation of the atrioventric-
ular junction plus pacing “ablate and pace” as well
as electrical isolation of pulmonary vein (PVI) are
effective non-pharmacological therapeutic strate-
gies in patients with refractory AF. In this case, the
role of long-term anticoagulation after successful
ablation is uncertain, since the embolic risk has
not yet been well defined [14, 15]. A recent clini-
cal trial provides very new information concern-
ing the widely used routine strategy of rhythm-
control, which does not reduce the rate of death
from cardiovascular causes, compared with simple
rate-control treatment [16].
However, and even if new medication guide-
lines are still being developed, many patients con-
tinue to require anticoagulation therapy and up to
3% of them, according to foreign data are ex-
posed to the risk of severe haemorrhagic compli-
cations and non-compliance problems [17]. In
Switzerland, management of oral anticoagulation
and its major bleeding complications are never-
theless lower (0.6%) [18, 19].
Atripump® introduces a completely new con-
cept for treating AF. It is a motorless volume-
displacing device based on artificial muscle tech-
nology that could restore the pump function of
normal atrium. Actual shape memory alloys en-
able the construction of micro-actuators that
move, and therefore work by changing their mo-
lecular structure when low voltage is applied to
them. Positioned on the external surface of the
atrium, they compress the heart chamber with the
potential for avoiding chronic anticoagulation,
and do not have other limitations of the current
cardiac assistance devices such as intrusive tubes
and a heavy power supply.
A first publication by our team has already
demonstrated the atripump to completely repro-
duce haemodynamic performance in a bench
model. It ran for three consecutive months with-
out any technical failure. The Starling law was re-
spected and temperatures were compatible with
those of the human body [20]. As a continuation,
the second aim was to assess these mechanical ef-
fects in an appropriately designed animal study.
Methods
Atripump® (Nanopowers SA, Lausanne, Switzer-
land) is a dome shape, silicone coated nitinol actuator 
5 mm high, set on a plastic ring 40 mm in diameter. The
thickness of this membrane is about 3 mm. 
Stochiometric Nickel-Titanium alloys (nitinols) un-
dergo a diffusionless martensitic transition at tempera-
tures near 70 °C with marked changes in physical proper-
ties such as shape or hardness, and do so with great force.
Figures 1 and 2
Dome is made of nitinol fibers, linked up to a ring and covered with a double layer of silicon. It is then placed on the external
surface of right atrium.
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The underlying explanation is a crystal structure that co-
operatively moves to another one at a specific tempera-
ture. It is a reversible phenomenon that can be endlessly
repeated without any permanent damage. When the niti-
nol wires are electrically heated, they provide a replica-
tive contractile function reminiscent of normal myocar-
dial contractility, therefore pulling down the apex of the
dome. When the electricity is cut off, the wires quickly
elongate and get back to their rest length. The outcome
of such a cycle in changing the dome’s concavity is vol-
ume displacement. Our atripump has a pacemaker-like
control unit that senses ventricular activity and delivers
the electrical kick following a dedicated algorithm. The
trigger comes from a lead placed on the epicardium and
connected to the control unit. The control unit senses
ventricular activity just like standard pacemakers (QRS
or ventricular depolarization) and after a given delay
(from 200 to 500 ms) activates the wires. It can also work
in a fixed mode without triggers, just like standard VVI
pacemakers. In preliminary experiments this homemade
control unit was placed outside the body. 
Five adult sheep (weight 65 ± 4 kg) were anaes-
thetised and ventilated to maintain a PaCO2 of 35–45
mm Hg. Throughout the procedure, analgesia was main-
tained and mean arterial blood pressure monitored. The
surgical approach was right thoracotomy in the 4th inter-
costal space after sterile preparation. The right atrium
(RA) was exposed and the dome sutured onto the epi-
cardium in order to provide the mechanical support for
blood circulation. AF was induced using rapid epicardial
pacing (600 bpm, Biotronik, Germany). Animals did not
receive any anticoagulation treatment.
A Swan-Ganz catheter was inserted in the left jugu-
lar vein to measure the central venous and pulmonary
pressure. A flowmeter was set around the pulmonary ar-
tery and computed ejection fraction (EF) of the RA was
obtained with an intracardiac ultrasound (ICUS) inserted
in the right jugular vein. That also allowed calculation of
systolic and diastolic surface areas of the RA. A tempera-
ture probe was placed in, between the inner silicone
membrane and the epicardium, right in the middle of 
the dome. All the major parameters were acquired under
3 conditions: baseline, AF and atripump assisted AF
(aaAF). The experiment ran successfully for two consecu-
tive hours in all animals and data acquisition occurred for
20 min in each haemodynamic situation (baseline, AF and
assisted AF). All the devices were correctly sewn and their
contractions were supplied with a power of 12 V, 400 mA
for 200 ms. State ethics committee, in accordance with
the Helsinki declaration, approved the animal proce-
dures. Sheep were sacrificed at the end of the experience.
Figure 3
Intra-operative view of the dome, being sewed and 
connected.
Figure 4
ICUS (intra cardiac ultra sound) assessed measures.
All data were gathered and sored using dedicate softwares.
Results
In two animals, after 20 min of AF, a small
thrombus appeared in the right atrial appendix
(ICUS assessed) and was washed out once the
pump was turned on.
Mean heart rate (bpm) increased from 67 ± 12
(baseline) to 89 ± 29 as soon as AF was induced
and stayed at 85 ± 21 under atrial assistance
(aaAF).
Concerning the two arterial pressure records,
mean arterial pressure (mm Hg) showed the fol-
lowing values; 75 ± 22 (baseline), 70 ± 13 (AF), and
69 ± 22 (aaAF). For mean pulmonary pressure
(mm Hg) we observed the following: 16 ± 2 (base-
line), 15 ± 2 (AF) and 17 ± 3 (aaAF). Central ve-
nous pressures (cmH2O) rose from a 8 ± 2 baseline
value to 15 ± 6 during AF and went back to 12 ± 5
after atrial assistance started running.
Right atrial surface area (cm2) presented the
following pattern: in diastole 6.8 ± 0.3 (baseline),
6.5 ± 0.1 (AF) and 6.4 ± 0.2 (aaAF), whilst in sys-
tole the surface area started at 5.2 ± 0.3 (baseline),
then reached 6.2 ± 0.1 (AF) and declined, 5.4 ± 0.3
with assistance (aaAF). A statistically relevant
change was observed for the right atrial ejection
fraction (%). Baseline values were 31%. They fell
to 5% in AF and rose to 20% in aaAF. Detailed re-
sults are presented in figure 5:
82-87 Abdel 12531.qxp  27.1.2009  13:53 Uhr  Seite 84
85S W I S S  M E D  W K LY 2 0 0 9 ; 13 9 ( 5 – 6 ) : 8 2 – 8 7  ·  w w w. s m w. ch
Baseline AF aaAF
Mean heart rate (bpm) 67±12 89±29 85±21
Mean art. press. (mm Hg) 75±22 70±13 69±22
Mean pulm. Press. (mm Hg) 16±2 15±2 17±3
Central venous press. (cmH2O) 8±2 15±6 12±5
RA diastolic surface (cm2) 6.8±0.3 6.5±0.1 6.4±0.2
RA systolic surface (cm2) 5.2±0.3 6.2±0.1 5.4±0.3
RA ejection fraction (%) 31 5 20
We propose a new surgical concept for the
management of chronic AF. Atripump is a labora-
tory-made prototype based on smart material
technology and intended to restore the mechani-
cal function of fibrillating atria. An implantable
battery, to be charged by the transcutaneous elec-
tromagnetic energy transfer (TEET) will power
the system. Intraoperatively, the device is sewn
over the diseased atrium and connected to the
battery as well as to a control unit, which can be
set according to the patient’s needs. 
The idea of using nitinol actuators to help a
deficient heart is not new and potential advan-
tages were investigated, mainly in ventricular as-
Discussion
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A
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baseline AF assisted AF
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Mean pulmonary pressure mm Hg
baseline AF assisted AF
C
RA diastolic surface cm2
RA ejection fraction %
baseline AF assisted AF
baseline AF assisted AF
E
G H
Central venous pressure cmH2O
baseline AF assisted AF
D
RA systolic surface cm2
baseline AF assisted AF
F
Figure 5
Results.
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sistance, from the early 70’s [21]. At that time,
contraction speed, material fatigue, heating and
energy supply were the major limitations. 
Today’s alloys are different and our approach
is totally novel. In a previous assay atripump suc-
cessfully reproduced haemodynamic performance
in a bench model [20]. Data made us confident
that the device in question should last for several
years before fibre-fracture occurs. The device
even seemed to follow the Franck-Starling law,
responding to increasing preload, thus behaving
in a similar fashion to natural muscle. This animal
study unmasks some relevant “in vivo” and clini-
cal outcomes.
All the devices ran without any technical fail-
ure. Mean heart rate increased, as soon as AF was
induced, because of the conduction properties of
the AV node controlling ventricular rate. Atrial
assistance does not influence this haemodynamic
value, which can better be dealt with by the PVI
procedure or antiarrythmic pharmacotherapy.
The temperature probe placed on the atrial sur-
face, revealed a mean value of 39 ± 1 ºC, demon-
strating that the amount of caloric energy trans-
ferred by the device onto surrounding structures
is very low. In this case, blood circulation and the
wet environment may have performed together as
a heat exchanger, keeping the organ temperature
in a range, compatible with human implantation. 
Considering the haemodynamic results illus-
trate atripump’s real purpose. First, during our ex-
periment, in two animals, after 20 min of AF, a
small thrombus appeared in the right atrial ap-
pendix (ICUS assessed) and was washed out once
the pump was turned on. Virchow’s triad encom-
passes three broad conditions, thought to con-
tribute to thrombosis. Hypercoagulability is not
an issue here. Our experiment had no direct effect
on the surfaces exposed to blood (no endothelial
injury). However, alteration of blood flow is pre-
vented (stasis).
Additionally to thromboembolism, AF can
also lead to clinical consequences including an
upstream congestion and a fall in backward blood
pressure, both of which contribute to heart failure
[22, 23]. Although we based our research on the
right-sided heart, analogous effects occur in left
cardiac function.
Central venous pressure seemed to reproduce
the congestive corollary during AF. Fibrillation
also gave rise to a significant RA systolic surface
extension (close to 1 cm2), while diastolic observa-
tions went on stand by. Up to this point one
might hesitate in concluding that intraoperative
haemodynamic support, or a real consequence of
AF provoked these changes. What may reinforce
the AF hypothesis and therefore suggest a lack of
atrial draining activity, is the immediate and sub-
stantial redress of these values after atripump was
switched on. Central venous pressure slightly re-
fined when RA systolic surface was corrected.
More relevantly, loss of the atrial work was
demonstrated by its EF, which fell from a 30%
(baseline) to about 5%. With atrial assistance run-
ning, it climbed to 20%. Successfully finding or
defining a cut-off value for a left atrial EF able to
prevent thrombosis would be interesting.
Many studies have shown how influential
atrial mechanical activity is. Schimpf et al.
brought left atrial “kick” recovery forward, as an
element for improvement in respiratory function
and contribution to normalisation of pulmonary
arterial pressure [24]. In the early 80’s, Linderer et
al. elegantly demonstrated that atrial systole en-
hances LV performance by means of the Franck-
Starling principle, increasing preload (end-dias-
tolic fibre’s length). In addition during induced
withdrawal of atrial function they remained rela-
tively full, accounting for increased pericardial
pressure. As a result, LV stroke-volumes were re-
duced with a resultant reduction in function [25].
Restoration of left atrial EF could have a positive
influence, still to be determined, in chronic HF. 
A further area of concern requires analysis to
establish whether the pressure imposed by the
dome structure on the atrial surface results in
functional obstruction of the coronary ramifica-
tion. We are mindful that the pump depicted in
this paper has been elaborated for the right
atrium and does not match the complex left atrial
field. A figure-of-eight or oval configuration
would better fit this anatomy. However, only
long-term animal studies will confirm applicabil-
ity and safety of our device.
Conclusion
Atripump represents a new strategy in restor-
ing the atrial blood transport. One key advantage
of this proposed technology is the tremendous
simplification in engineering since the material it-
self is the motor. Our experiment showed a re-
trieval of the atrial “kick” and a possible beneficial
effect on thrombembolic events. Were a plausible
model to be realised, it could eliminate the need
for anticoagulation drug therapy. Also, it opens
new avenues in the management of end-stage HF.
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